ImmunoGen, Inc. (IMGN): Price and Financial Metrics


ImmunoGen, Inc. (IMGN): $5.90

0.07 (+1.20%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add IMGN to Watchlist
Sign Up

Industry: Biotech


Ranked

of 509

in industry

IMGN POWR Grades


  • Value is the dimension where IMGN ranks best; there it ranks ahead of 75.83% of US stocks.
  • IMGN's strongest trending metric is Momentum; it's been moving down over the last 52 weeks.
  • IMGN's current lowest rank is in the Momentum metric (where it is better than 4.48% of US stocks).

IMGN Stock Summary

  • Of note is the ratio of ImmunoGen Inc's sales and general administrative expense to its total operating expenses; only 10.74% of US stocks have a lower such ratio.
  • For IMGN, its debt to operating expenses ratio is greater than that reported by merely 14.9% of US equities we're observing.
  • Revenue growth over the past 12 months for ImmunoGen Inc comes in at 58.05%, a number that bests 88.79% of the US stocks we're tracking.
  • Stocks that are quantitatively similar to IMGN, based on their financial statements, market capitalization, and price volatility, are WVE, MGNX, ABUS, PTGX, and NRIX.
  • IMGN's SEC filings can be seen here. And to visit ImmunoGen Inc's official web site, go to www.immunogen.com.

IMGN Valuation Summary

  • In comparison to the median Healthcare stock, IMGN's price/earnings ratio is 160% lower, now standing at -21.9.
  • IMGN's price/earnings ratio has moved up 60.5 over the prior 243 months.
  • IMGN's EV/EBIT ratio has moved up 60 over the prior 243 months.

Below are key valuation metrics over time for IMGN.

Stock Date P/S P/B P/E EV/EBIT
IMGN 2021-08-31 8.9 17.8 -21.9 -18.0
IMGN 2021-08-30 8.7 17.4 -21.4 -17.5
IMGN 2021-08-27 9.0 17.9 -22.0 -18.1
IMGN 2021-08-26 8.5 17.0 -20.8 -16.9
IMGN 2021-08-25 8.3 16.6 -20.4 -16.5
IMGN 2021-08-24 8.2 16.3 -20.1 -16.2

IMGN Growth Metrics

  • Its 3 year net income to common stockholders growth rate is now at -34.48%.
  • Its year over year cash and equivalents growth rate is now at 14.48%.
  • Its 3 year cash and equivalents growth rate is now at 47.83%.
Over the past 30 months, IMGN's revenue has gone up $83,195,000.

The table below shows IMGN's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-06-30 136.641 -110.612 -55.778
2021-03-31 134.718 -94.926 -49.335
2020-12-31 132.299 -78.62 -44.372
2020-09-30 91.365 -119.712 -70.946
2020-06-30 86.457 -124.065 -70.322
2020-03-31 86.974 -126.885 -89.47

IMGN's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • IMGN has a Quality Grade of C, ranking ahead of 31% of graded US stocks.
  • IMGN's asset turnover comes in at 0.437 -- ranking 107th of 681 Pharmaceutical Products stocks.
  • RMTI, PTE, and GILD are the stocks whose asset turnover ratios are most correlated with IMGN.

The table below shows IMGN's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.437 1 1.612
2021-03-31 0.442 1 1.694
2020-12-31 0.452 1 2.339
2020-09-30 0.347 1 9.437
2020-06-30 0.327 1 10.967
2020-03-31 0.323 1 39.802

IMGN Price Target

For more insight on analysts targets of IMGN, see our IMGN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $9.79 Average Broker Recommendation 1.55 (Moderate Buy)

IMGN Stock Price Chart Interactive Chart >

Price chart for IMGN

IMGN Price/Volume Stats

Current price $5.90 52-week high $10.88
Prev. close $5.83 52-week low $4.97
Day low $5.70 Volume 851,100
Day high $5.90 Avg. volume 1,886,046
50-day MA $5.78 Dividend yield N/A
200-day MA $6.87 Market Cap 1.19B

ImmunoGen, Inc. (IMGN) Company Bio


Immunogen develops targeted anticancer therapeutics. The Company's ADC technology uses tumor-targeting antibodies to deliver an ImmunoGen cell-killing agent specifically to cancer cells. The company was founded in 1981 and is based in Waltham, Massachusetts.


IMGN Latest News Stream


Event/Time News Detail
Loading, please wait...

IMGN Latest Social Stream


Loading social stream, please wait...

View Full IMGN Social Stream

Latest IMGN News From Around the Web

Below are the latest news stories about ImmunoGen Inc that investors may wish to consider to help them evaluate IMGN as an investment opportunity.

WisdomTree Investments, Inc. (WETF) Reports Next Week: Wall Street Expects Earnings Growth

ImmunoGen (IMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Entrepreneur.com | October 22, 2021

Analysts Estimate ImmunoGen (IMGN) to Report a Decline in Earnings: What to Look Out for

ImmunoGen (IMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | October 22, 2021

Antibody Drug Conjugates Market Expoler Future Growth With Top Key Players like Hoffmann-La Roche Ltd, Seattle Genetics, Takeda, ImmunoGen Inc.

Antibody drug conjugate (ADC) is a class of biopharmaceutical drugs indicated as a targeted therapy for treating cancer. ADC is are designed to kill only cancer cells and spare healthy cells, which makes it more effective than traditional cancer treatment

OpenPR | October 19, 2021

ImmunoGen Announces Conference Call to Discuss Its Third Quarter 2021 Operating Results

WALTHAM, Mass., October 14, 2021--ImmunoGen Announces Conference Call to Discuss Its Third Quarter 2021 Operating Results

Yahoo | October 14, 2021

ImmunoGen: Important Catalysts Ahead

I covered ImmunoGen (IMGN) twice in the last couple years. In 2019, I discussed the company’s leadership position in ADC technology and its list of licensing partners. I discussed why it failed the FORWARD 1 trial, and the then soon-to-begin SOROYA trial in patients with high FRα expression. In my...

Avisol Capital Partners on Seeking Alpha | October 10, 2021

Read More 'IMGN' Stories Here

IMGN Price Returns

1-mo -3.28%
3-mo 5.73%
6-mo -27.52%
1-year 8.06%
3-year 0.34%
5-year 159.91%
YTD -8.53%
2020 26.35%
2019 6.35%
2018 -25.12%
2017 214.22%
2016 -84.97%

Continue Researching IMGN

Want to see what other sources are saying about ImmunoGen Inc's financials and stock price? Try the links below:

ImmunoGen Inc (IMGN) Stock Price | Nasdaq
ImmunoGen Inc (IMGN) Stock Quote, History and News - Yahoo Finance
ImmunoGen Inc (IMGN) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 2.1496 seconds.